US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Everus Construction Group, Inc.

117.31

+2.221.93%

Post-market: 117.310.00000.00%19:41 EDT

Volume:353.76K

Turnover:41.37M

Market Cap:5.98B

PE:29.70

High:119.30

Open:115.51

Low:115.13

Close:115.09

52wk High:137.64

52wk Low:31.38

Shares:51.01M

Float Shares:50.85M

Volume Ratio:0.64

T/O Rate:0.70%

Dividend:- -

Dividend Rate:- -

EPS(TTM):3.95

EPS(LYR):3.95

ROE:38.34%

ROA:10.97%

PB:9.50

PE(LYR):29.70

Loading ...

Overview Company News Filings

Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

Everus Construction Group Inc. to Announce Fourth Quarter and Full-Year Results via Webcast

Everus Construction Group Inc : Stifel Cuts Target Price to $107 From $110

THOMSON REUTERS

A Look At Everus Construction Group (ECG) Valuation After Strong Third Quarter Earnings Surprise

Simply Wall St.

Cantor Fitzgerald Initiates Everus Construction at Neutral With $97 Price Target

MT Newswires Live

Everus Construction initiated with a Neutral at Cantor Fitzgerald

Everus Construction Group Initiated at Neutral by Guggenheim

Guggenheim Initiates Coverage on Everus Construction With Neutral Rating

MT Newswires Live

Press Release: PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Everus Construction Group (ECG): Assessing Valuation After a 29% One-Year Share Price Gain

Simply Wall St.

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

OMRON Healthcare Unveils Global ECG Strategy

Why Is Micro Cap HeartBeam Stock Surging On Wednesday?

Benzinga_recent_news

Director Helena Mercedes Hernandez Acquires Common Shares of Everus Construction Group Inc

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

iRhythm Technologies (IRTC) Valuation After New Global Zio ECG Data From Major Cardiac Conference

Simply Wall St.

Zio ECG Study Shows Cross-Population Efficacy and Might Change The Case For Investing In iRhythm Technologies (IRTC)

Simply Wall St.

Transtek Medical Electronics' Unit Renews Registration Certificate for ECG Information Network Software

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ECG/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ECG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ECG\",,,,,undefined,":{"symbol":"ECG","market":"US","secType":"STK","nameCN":"Everus Construction Group, Inc.","latestPrice":117.31,"timestamp":1774641600000,"preClose":115.09,"halted":0,"volume":353759,"hourTrading":{"tag":"盘后","latestPrice":117.31,"preClose":117.31,"latestTime":"19:41 EDT","volume":15657,"amount":1836823.29,"timestamp":1774654869138,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.019289251889825342,"floatShares":50847531,"shares":51006575,"eps":3.95,"marketStatus":"Market Closed","change":2.22,"latestTime":"03-27 16:00:00 EDT","open":115.51,"high":119.2967,"low":115.13,"amount":41368616.37349,"amplitude":0.036204,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.95,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":115.09,"preHourTrading":{"tag":"盘前","latestPrice":113,"preClose":115.09,"latestTime":"08:00 EDT","volume":2,"amount":226,"timestamp":1774612800802,"change":-2.09,"changeRate":-0.01816,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":117.31,"preClose":117.31,"latestTime":"19:41 EDT","volume":15657,"amount":1836823.29,"timestamp":1774654869138,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.641631,"impliedVol":0.6661,"impliedVolPercentile":0.7692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ECG\",,,,,undefined,":{"symbol":"ECG","floatShares":50847531,"roa":"10.97%","roe":"38.34%","lyrEps":3.95,"volumeRatio":0.641631,"shares":51006575,"dividePrice":0,"high":119.2967,"amplitude":0.036204,"preClose":115.09,"low":115.13,"week52Low":31.38,"pbRate":"9.50","psRate":"1.60","week52High":137.64,"institutionHeld":0,"latestPrice":117.31,"eps":3.95,"divideRate":0,"volume":353759,"delay":0,"ttmEps":3.95,"open":115.51,"prevYearClose":85.56,"prevWeekClose":110.95,"prevMonthClose":120.87,"prevQuarterClose":85.56,"fiveDayClose":110.95,"twentyDayClose":120.87,"sixtyDayClose":87.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ECG\",params:#limit:5,,,undefined,":[{"date":"2026-02-24","symbol":"ECG","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":0.72,"defaultRemindTime":1771966800000,"name":null,"time":"Post Market","dateTimestamp":1771909200000,"actualEps":null},{"market":"US","date":"2025-11-04","symbol":"ECG","fiscalQuarterEnding":"2025/09","expectedEps":0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":1.11},{"market":"US","date":"2025-08-12","symbol":"ECG","fiscalQuarterEnding":"2025/06","expectedEps":0.61,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":1.03},{"market":"US","date":"2025-05-13","symbol":"ECG","fiscalQuarterEnding":"2025/03","expectedEps":0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":0.72},{"market":"US","date":"2025-02-11","symbol":"ECG","fiscalQuarterEnding":"2024/12","expectedEps":0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.67}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ECG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ECG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.1429,"hold":0.5714,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1429,"analysts":7,"updateTime":1769140800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ECG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ECG","date":"2026-03-27","current":29.698734,"percent":0.944606,"low":11.94786,"twenty":20.948708,"median":24.302633,"eighty":26.689853,"high":32.888805,"avg":23.299595,"sd":4.700427,"marketCap":5870363289},"quantilePoints":[{"date":"2024-11-15","current":19.884731,"twenty":20.580031,"median":21.388177,"eighty":22.118522,"marketCap":2892154627},{"date":"2024-11-22","current":22.527151,"twenty":20.580031,"median":21.221711,"eighty":22.118522,"marketCap":3276483952},{"date":"2024-11-29","current":22.309869,"twenty":20.774883,"median":21.784189,"eighty":22.44935,"marketCap":3244881275},{"date":"2024-12-06","current":23.914946,"twenty":20.948708,"median":22.309869,"eighty":22.694667,"marketCap":3478333306},{"date":"2024-12-13","current":24.1112,"twenty":21.255005,"median":22.386969,"eighty":23.504916,"marketCap":3506877659},{"date":"2024-12-20","current":22.639296,"twenty":21.463875,"median":22.621773,"eighty":23.900227,"marketCap":3292795011},{"date":"2024-12-27","current":25.796882,"twenty":21.726014,"median":22.804009,"eighty":24.031297,"marketCap":3752053262},{"date":"2025-01-03","current":24.279418,"twenty":22.045628,"median":23.042317,"eighty":24.098584,"marketCap":3531344247},{"date":"2025-01-10","current":23.36123,"twenty":22.054038,"median":23.36123,"eighty":24.167273,"marketCap":3397797452},{"date":"2025-01-17","current":23.231562,"twenty":22.309869,"median":23.296396,"eighty":24.223346,"marketCap":3378937791},{"date":"2025-01-24","current":26.403166,"twenty":22.309869,"median":23.448843,"eighty":24.416796,"marketCap":3840234925},{"date":"2025-01-31","current":24.703467,"twenty":22.363139,"median":23.511925,"eighty":24.431515,"marketCap":3593020438},{"date":"2025-02-07","current":24.784071,"twenty":22.393278,"median":23.631079,"eighty":24.431515,"marketCap":3604744012},{"date":"2025-02-14","current":17.609659,"twenty":22.363139,"median":23.694161,"eighty":24.484083,"marketCap":2525594974},{"date":"2025-02-21","current":16.543269,"twenty":22.049833,"median":23.511925,"eighty":24.443431,"marketCap":2372652202},{"date":"2025-02-28","current":14.893919,"twenty":20.948708,"median":23.398027,"eighty":24.417497,"marketCap":2136100715},{"date":"2025-03-07","current":14.060071,"twenty":19.828659,"median":23.326185,"eighty":24.358924,"marketCap":2016509475},{"date":"2025-03-14","current":13.437787,"twenty":16.836882,"median":23.135188,"eighty":24.308591,"marketCap":1927260826},{"date":"2025-03-21","current":14.294761,"twenty":15.304834,"median":22.94419,"eighty":24.287829,"marketCap":2050168965},{"date":"2025-03-28","current":12.43502,"twenty":14.540119,"median":22.651562,"eighty":24.245775,"marketCap":1783443003},{"date":"2025-04-04","current":12.555921,"twenty":14.128344,"median":22.527151,"eighty":24.214935,"marketCap":1800782740},{"date":"2025-04-11","current":13.501793,"twenty":13.910012,"median":22.343162,"eighty":24.184095,"marketCap":1936440687},{"date":"2025-04-17","current":13.572911,"twenty":13.722422,"median":22.181953,"eighty":24.146246,"marketCap":1946640532},{"date":"2025-04-25","current":14.568566,"twenty":13.695946,"median":21.51434,"eighty":24.113303,"marketCap":2089438371},{"date":"2025-05-02","current":15.233522,"twenty":13.71017,"median":20.922073,"eighty":24.085968,"marketCap":2184806927},{"date":"2025-05-09","current":17.164381,"twenty":13.722422,"median":19.902399,"eighty":24.031297,"marketCap":2461732735},{"date":"2025-05-16","current":20.563833,"twenty":13.745616,"median":19.893565,"eighty":23.999055,"marketCap":3123214340},{"date":"2025-05-23","current":21.992869,"twenty":13.78911,"median":20.563833,"eighty":23.959104,"marketCap":2926865953},{"date":"2025-05-30","current":22.176813,"twenty":13.823958,"median":20.788901,"eighty":23.91004,"marketCap":2951345752},{"date":"2025-06-06","current":23.146354,"twenty":13.877297,"median":21.451259,"eighty":23.877799,"marketCap":3080374692},{"date":"2025-06-13","current":23.161683,"twenty":13.948415,"median":21.770602,"eighty":23.816119,"marketCap":3082414675},{"date":"2025-06-20","current":22.912591,"twenty":13.971173,"median":22.043525,"eighty":23.771261,"marketCap":3049264947},{"date":"2025-06-27","current":23.740342,"twenty":14.060071,"median":22.121246,"eighty":23.740342,"marketCap":3159424042},{"date":"2025-07-03","current":24.970471,"twenty":14.07145,"median":22.251005,"eighty":23.895321,"marketCap":3323132697},{"date":"2025-07-11","current":25.805886,"twenty":14.153947,"median":22.376456,"eighty":24.052477,"marketCap":3434311784},{"date":"2025-07-18","current":26.518671,"twenty":14.202307,"median":22.526346,"eighty":24.175684,"marketCap":3529171005},{"date":"2025-07-25","current":26.442027,"twenty":14.212264,"median":22.621773,"eighty":24.30109,"marketCap":3518971089},{"date":"2025-08-01","current":28.457753,"twenty":14.278404,"median":22.671329,"eighty":24.416796,"marketCap":3787228885},{"date":"2025-08-08","current":27.411568,"twenty":14.30614,"median":22.782297,"eighty":24.537352,"marketCap":3648000028},{"date":"2025-08-15","current":23.175295,"twenty":14.422774,"median":22.810398,"eighty":24.635911,"marketCap":3841305163},{"date":"2025-08-22","current":23.323006,"twenty":14.493892,"median":22.904927,"eighty":24.537352,"marketCap":3865788319},{"date":"2025-08-29","current":24.713955,"twenty":14.521629,"median":22.920255,"eighty":24.537352,"marketCap":4096338038},{"date":"2025-09-05","current":23.815378,"twenty":14.551498,"median":22.978193,"eighty":24.507914,"marketCap":3947398839},{"date":"2025-09-12","current":24.372372,"twenty":14.649641,"median":23.042317,"eighty":24.488989,"marketCap":4039720740},{"date":"2025-09-19","current":25.200171,"twenty":14.753844,"median":23.089828,"eighty":24.488989,"marketCap":4176928426},{"date":"2025-09-26","current":24.396991,"twenty":14.851263,"median":23.146354,"eighty":24.588002,"marketCap":4043801266},{"date":"2025-10-03","current":25.117084,"twenty":14.97923,"median":23.180649,"eighty":24.722376,"marketCap":4163156651},{"date":"2025-10-10","current":27.003481,"twenty":15.154555,"median":23.193759,"eighty":24.845751,"marketCap":4475826956},{"date":"2025-10-17","current":27.852821,"twenty":15.383802,"median":23.275964,"eighty":25.02914,"marketCap":4616605103},{"date":"2025-10-24","current":26.926548,"twenty":15.791108,"median":23.323006,"eighty":25.217404,"marketCap":4463075312},{"date":"2025-10-31","current":27.600481,"twenty":16.024903,"median":23.341955,"eighty":25.414653,"marketCap":4574779711},{"date":"2025-11-07","current":27.713121,"twenty":16.093341,"median":23.36123,"eighty":25.523906,"marketCap":5014966454},{"date":"2025-11-14","current":25.813341,"twenty":16.136723,"median":23.428153,"eighty":25.800484,"marketCap":4671182138},{"date":"2025-11-21","current":22.66771,"twenty":16.383495,"median":23.439945,"eighty":25.708429,"marketCap":4101948761},{"date":"2025-11-28","current":25.92045,"twenty":16.548957,"median":23.449096,"eighty":25.737913,"marketCap":4690564637},{"date":"2025-12-05","current":26.630754,"twenty":16.561288,"median":23.487393,"eighty":25.810359,"marketCap":4819101206},{"date":"2025-12-12","current":28.527716,"twenty":16.749451,"median":23.659866,"eighty":25.855971,"marketCap":5162375455},{"date":"2025-12-19","current":24.578765,"twenty":17.031279,"median":23.716749,"eighty":25.83416,"marketCap":4447773340},{"date":"2025-12-26","current":25.272157,"twenty":17.057186,"median":23.738426,"eighty":25.81185,"marketCap":4573249514},{"date":"2026-01-02","current":24.116504,"twenty":17.112011,"median":23.784087,"eighty":25.805886,"marketCap":4364122557},{"date":"2026-01-09","current":24.601314,"twenty":17.164381,"median":23.827333,"eighty":25.805886,"marketCap":4451853866},{"date":"2026-01-16","current":25.170685,"twenty":17.266247,"median":23.880592,"eighty":25.796882,"marketCap":4554887147},{"date":"2026-01-23","current":25.948637,"twenty":17.540977,"median":23.951744,"eighty":25.84491,"marketCap":4695665294},{"date":"2026-01-30","current":25.940181,"twenty":17.774022,"median":24.037581,"eighty":25.850684,"marketCap":4694135097},{"date":"2026-02-06","current":25.07485,"twenty":19.358663,"median":24.060792,"eighty":25.850684,"marketCap":4537544912},{"date":"2026-02-13","current":28.544628,"twenty":19.856695,"median":24.113685,"eighty":25.941872,"marketCap":5165435850},{"date":"2026-02-20","current":29.463513,"twenty":19.895332,"median":24.116504,"eighty":26.181969,"marketCap":5331717284},{"date":"2026-02-27","current":30.881602,"twenty":20.109789,"median":24.148919,"eighty":26.329202,"marketCap":6230980793},{"date":"2026-03-06","current":28.303079,"twenty":20.437519,"median":24.175424,"eighty":26.394077,"marketCap":5710712259},{"date":"2026-03-13","current":28.548292,"twenty":20.677847,"median":24.216336,"eighty":26.448787,"marketCap":5760188776},{"date":"2026-03-20","current":29.706099,"twenty":20.774883,"median":24.279418,"eighty":26.529401,"marketCap":5993799549},{"date":"2026-03-27","current":29.094332,"twenty":20.948708,"median":24.302633,"eighty":26.689853,"marketCap":5870363289}],"updateTime":1774749213612},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ECG\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607033704","title":"Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals","url":"https://stock-news.laohu8.com/highlight/detail?id=2607033704","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607033704?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:30","pubTimestamp":1769693400,"startTime":"0","endTime":"0","summary":"Southlake, TX, Jan.  29, 2026  (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/29/3228577/0/en/Cibolo-Health-Designates-HeartSciences-MyoVista-Insights-as-Endorsed-ECG-Management-Platform-for-Network-of-123-Independent-Hospitals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2607233887","title":"Everus Construction Group Inc. to Announce Fourth Quarter and Full-Year Results via Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2607233887","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607233887?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:30","pubTimestamp":1769635837,"startTime":"0","endTime":"0","summary":"Everus Construction Group Inc. will release its fourth quarter and full-year 2025 financial results after the market closes on February 24, 2025. Company leadership will host a webcast to review results, discuss recent events, and conduct a Q&A session at 10:30 a.m. EST on February 25, 2025. The webcast and presentation materials will be available under the \"Events & Presentations\" tab on the Everus investor website. Participants can also listen by phone using USA Toll-Free: 800-715-9871 or International Toll: 646-307-1963 with Conference ID: 1034822.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everus Construction Group Inc. published the original content used to generate this news brief via Business Wire  on January 28, 2026, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL7k0Sxh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ECG","BK4129"],"gpt_icon":0},{"id":"2606174372","title":"Everus Construction Group Inc : Stifel Cuts Target Price to $107 From $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2606174372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606174372?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:19","pubTimestamp":1769429943,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2606825909","title":"A Look At Everus Construction Group (ECG) Valuation After Strong Third Quarter Earnings Surprise","url":"https://stock-news.laohu8.com/highlight/detail?id=2606825909","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606825909?lang=en_us&edition=fundamental","pubTime":"2026-01-25 15:21","pubTimestamp":1769325700,"startTime":"0","endTime":"0","summary":"Everus Construction Group (ECG) is back in focus after third quarter 2025 earnings came in well ahead of analyst expectations, with EPS 52.05% higher and revenue 30% above the prior year.\nSee our latest analysis for Everus Construction Group.\nThe strong third quarter update comes after a mixed few months in the market, with a small 1.25% 1 month share price return and a 2.29% year to date share price gain. The 1 year total shareholder return of 18.84% points to momentum that has been building...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/a-look-at-everus-construction-group-ecg-valuation-after-stro","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/a-look-at-everus-construction-group-ecg-valuation-after-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ECG","ECG.AU"],"gpt_icon":0},{"id":"2605477760","title":"Cantor Fitzgerald Initiates Everus Construction at Neutral With $97 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605477760","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605477760?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:40","pubTimestamp":1769172025,"startTime":"0","endTime":"0","summary":"Everus Construction Group, Inc. (ECG) has an average rating of overweight and mean price target of $104.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7064","BK4129","ECG","ECG.AU"],"gpt_icon":0},{"id":"2605220474","title":"Everus Construction initiated with a Neutral at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2605220474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605220474?lang=en_us&edition=fundamental","pubTime":"2026-01-23 19:35","pubTimestamp":1769168157,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Everus Construction (ECG) with a Neutral rating and $97 price target The Engineering & Construction sector ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/everus-construction-initiated-with-a-neutral-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/everus-construction-initiated-with-a-neutral-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ECG","BK4129"],"gpt_icon":0},{"id":"2605491027","title":"Everus Construction Group Initiated at Neutral by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605491027?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:34","pubTimestamp":1769088840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ECG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 08:34 ET (13:34 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2605968495","title":"Guggenheim Initiates Coverage on Everus Construction With Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2605968495","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605968495?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:13","pubTimestamp":1769083983,"startTime":"0","endTime":"0","summary":"Everus Construction Group, Inc. (ECG) has an average rating of Overweight and mean price target of $106.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4129","ECG","ECG.AU","BK7064"],"gpt_icon":0},{"id":"2603528815","title":"Press Release: PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2603528815","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603528815?lang=en_us&edition=fundamental","pubTime":"2026-01-13 02:25","pubTimestamp":1768242300,"startTime":"0","endTime":"0","summary":"BELFAST, Northern Ireland  , Jan. 12, 2026 /PRNewswire/ -- PulseAI, a rapidly emerging leader in AI-enabled cardiac diagnostics, today announced the closing of its seed funding round, led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The investment will enable PulseAI to scale deployment of its AI-ECG technology and advance its pathway through US FDA 510 clearance.Over 300 million electrocardiograms  are performed annually worldwide. However, despite the critical importance of the ECG as a frontline diagnostic tool, its interpretation remains highly dependent on specialist training and manual analysis. This often leads to delays, diagnostic variability, and missed opportunities for early intervention. PulseAI's AI-ECG platform is designed to address this challenge directly by delivering high-performance clinical decision support in both primary and acute care settings.As part of the round, Dr. Justin Mortara, an experienced inn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: PulseAI Secures Seed Funding to Advance AI-Driven ECG Diagnostics","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AI","BK4129","ECG"],"gpt_icon":0},{"id":"2601224870","title":"Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2601224870","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601224870?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:00","pubTimestamp":1767787200,"startTime":"0","endTime":"0","summary":"- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/07/3214380/0/en/Syndax-and-World-Orphan-Drug-Alliance-to-Launch-a-Multi-Regional-Managed-Access-Program-Expanding-Access-to-Revuforj-revumenib-Outside-the-U-S.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ALL","ECG","LU1571399168.USD","LU2355687059.USD","BK4107","LU1699723380.USD","BK4588","LU0985320562.USD","BK4533","BK4585"],"gpt_icon":0},{"id":"2593134451","title":"Everus Construction Group (ECG): Assessing Valuation After a 29% One-Year Share Price Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2593134451","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593134451?lang=en_us&edition=fundamental","pubTime":"2025-12-23 05:12","pubTimestamp":1766437972,"startTime":"0","endTime":"0","summary":"Everus Construction Group (ECG) has quietly outperformed the broader market this year, with the stock climbing about 29% over the past year and nearly 8% in the past month. Investors are starting to notice.\nSee our latest analysis for Everus Construction Group.\nThe latest leg higher, including a solid 1 month share price return of roughly 8% and a 1 year total shareholder return of about 29%, suggests momentum is still building as investors grow more comfortable with Everus Construction...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/everus-construction-group-ecg-assessing-valuation-after-a-29","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/everus-construction-group-ecg-assessing-valuation-after-a-29","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7064","DCF","BK4129","ECG","ECG.AU"],"gpt_icon":0},{"id":"2591263835","title":"Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591263835","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591263835?lang=en_us&edition=fundamental","pubTime":"2025-12-13 09:00","pubTimestamp":1765587600,"startTime":"0","endTime":"0","summary":"First FDA approved treatment in 30+ years for more than 2 million Americans with PSVTNovel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/13/3204944/0/en/Milestone-Receives-FDA-Approval-of-CARDAMYST-etripamil-as-First-and-Only-Self-Administered-Nasal-Spray-for-Adults-with-Paroxysmal-Supraventricular-Tachycardia-PSVT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","BK4096","SVT","ECG"],"gpt_icon":0},{"id":"2590505296","title":"Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505296","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505296?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540800,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  12, 2025  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204567/0/en/Revuforj-revumenib-Named-Best-New-Drug-at-the-Scrip-Awards-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","BK4585","LU1699723380.USD","LU1571399168.USD","ALL","BK4588","BK4107","ECG","LU2355687059.USD","BK4129","BK4533"],"gpt_icon":0},{"id":"2590567719","title":"OMRON Healthcare Unveils Global ECG Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590567719","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590567719?lang=en_us&edition=fundamental","pubTime":"2025-12-11 15:00","pubTimestamp":1765436400,"startTime":"0","endTime":"0","summary":"New services and strategic partnerships advance Going for ZERO visionTOKYO, Dec. 11, 2025 /PRNewswire/ -- OMRON Healthcare Co., Ltd. announced new initiatives to accelerate its global electrocardiogram  business strategy, positioning it as a key driver of the company's cardiovascular vision, Going for ZERO. The strategy, first presented at a press conference held in Tokyo on November 12, 2025, includes additional investment in Indian AI healthtech company Tricog Health India Private Limited and the planned transfer of the Heartnote ECG service business from JSR Corporation.\"Confronting the heart failure 'pandemic' and the shortage of cardiovascular specialists requires new approaches,\" said Ayumu Okada, President and CEO, OMRON Healthcare Co., Ltd. \"By combining innovative technology with strategic partnerships, we aim to take our cardiovascular business to the next stage and help prevent serious cardiac events before they occur.\"","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2843331/Speakers_OMRON_HEALTHCARE_press_conference_November_12_2025.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2843331/Speakers_OMRON_HEALTHCARE_press_conference_November_12_2025.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/omron-healthcare-unveils-global-ecg-strategy-302638788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","BK4581","LU0029874061.USD","BK4588","BK4137","BK4585","HCSG","ECG","XLV","CFA.SI","XBI","BK7064","BK4129","LABU","ECG.AU"],"gpt_icon":0},{"id":"2590397875","title":"Why Is Micro Cap HeartBeam Stock Surging On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590397875","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590397875?lang=en_us&edition=fundamental","pubTime":"2025-12-11 00:27","pubTimestamp":1765384020,"startTime":"0","endTime":"0","summary":"HeartBeam shares rise after FDA clears its 12-lead ECG software, boosting plans for a 2026 launch and expanded cardiac detection technology.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Chest-Pain-Illness-Causing-Heart-Attack-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Chest-Pain-Illness-Causing-Heart-Attack-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/12/49310554/why-is-micro-cap-heartbeam-stock-surging-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/12/49310554/why-is-micro-cap-heartbeam-stock-surging-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BEAT","BK4129","BK4082","ECG"],"gpt_icon":0},{"id":"2590610369","title":"Director Helena Mercedes Hernandez Acquires Common Shares of Everus Construction Group Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590610369","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590610369?lang=en_us&edition=fundamental","pubTime":"2025-12-09 06:11","pubTimestamp":1765231881,"startTime":"0","endTime":"0","summary":"Helena Mercedes Hernandez, Director of Everus Construction Group Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everus Construction Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL8QT9Jb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Helena Mercedes Hernandez Acquires Common Shares of Everus Construction Group Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2589533799","title":"Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589533799","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589533799?lang=en_us&edition=fundamental","pubTime":"2025-12-08 19:50","pubTimestamp":1765194600,"startTime":"0","endTime":"0","summary":"– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute le","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/08/3201378/0/en/Syndax-Highlights-Leadership-in-Menin-Inhibition-at-ASH-2025-with-Multiple-Revuforj-revumenib-Presentations-Spanning-the-Acute-Leukemia-Treatment-Continuum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2355687059.USD","OS","ASH","CR","BK4585","BK4107","BK4161","LU1699723380.USD","BK4109","ALL","BK4588","BK4097","LU0985320562.USD","BK4533","BK4129","ORR","LU2463526074.USD","LU1571399168.USD","HSCT","ECG"],"gpt_icon":0},{"id":"2588013769","title":"iRhythm Technologies (IRTC) Valuation After New Global Zio ECG Data From Major Cardiac Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588013769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588013769?lang=en_us&edition=fundamental","pubTime":"2025-12-03 15:19","pubTimestamp":1764746347,"startTime":"0","endTime":"0","summary":"iRhythm Technologies (IRTC) just used a major cardiac conference to show that its Zio ECG patch performs similarly for Asian and non Asian patients, a data driven win for its global expansion story.\nSee our latest analysis for iRhythm Technologies.\nThat backdrop helps explain why, even after a softer patch with a recent pullback in the 7 day share price return and some consolidation in the past month, iRhythm’s year to date share price return of over 100% and robust 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irtc/irhythm-technologies/news/irhythm-technologies-irtc-valuation-after-new-global-zio-ecg","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irtc/irhythm-technologies/news/irhythm-technologies-irtc-valuation-after-new-global-zio-ecg","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4129","ECG","IRTC","BK4563","BK4082"],"gpt_icon":0},{"id":"2586788187","title":"Zio ECG Study Shows Cross-Population Efficacy and Might Change The Case For Investing In iRhythm Technologies (IRTC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586788187","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586788187?lang=en_us&edition=fundamental","pubTime":"2025-11-28 15:18","pubTimestamp":1764314328,"startTime":"0","endTime":"0","summary":"iRhythm Technologies recently announced results from a large U.S. study presented at APHRS 2025, showing their Zio long-term ECG monitoring service delivered consistent performance and diagnostic yield for both Asian and non-Asian patients over a 14-day monitoring period.\nThis cross-population evidence, bolstered by advanced AI analytics and broad clinical validation, is especially relevant for global markets where differences in patient demographics and lifestyle can affect device...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irtc/irhythm-technologies/news/zio-ecg-study-shows-cross-population-efficacy-and-might-chan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-irtc/irhythm-technologies/news/zio-ecg-study-shows-cross-population-efficacy-and-might-chan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRTC","BK4129","BK4082","BK4563","ECG"],"gpt_icon":0},{"id":"2586243063","title":"Transtek Medical Electronics' Unit Renews Registration Certificate for ECG Information Network Software","url":"https://stock-news.laohu8.com/highlight/detail?id=2586243063","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586243063?lang=en_us&edition=fundamental","pubTime":"2025-11-27 17:10","pubTimestamp":1764234603,"startTime":"0","endTime":"0","summary":"Guangdong Transtek Medical Electronics'  unit, Shenzhen Ruikang Hongye Technology Development, renewed its medical device registration certificate for its ECG information network management system software, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese medical device manufacturer's shares closed 2% higher on Thursday.The Guangdong Provincial Medical Products Administration approved the renewal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4134","BK0114","III","BK0251","ECG","BK0109","BK4129","300562"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":97,"code":"91000000","status":"200"}]}}